Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure

Chemico-biological Interactions
Richard D IronsA Robert Schnatter

Abstract

We characterized the prevalence of hematopoietic and lymphoid disease for 2923 consecutive patients presenting at 29 hospitals from August 2003 to June 2007. Diagnoses were made in our laboratory using WHO criteria based on morphologic, immunophenotypic, cytogenetic, FISH and molecular data. A total of 611 subjects (322 males/289 females) were prospectively diagnosed with MDS using WHO (2001) criteria. Update and re-evaluation of cases using MDS (2008) criteria resulted in 649 MDS cases. Using WHO (2008) criteria, refractory cytopenia with multilineage dysplasia (RCMD) accounted for 68% of total cases, refractory anemia with excess blasts (RAEB), 16.3%; refractory anemia (RA), 6.5%; refractory cytopenia with unilineage dysplasia (RCUD), 4%; and MDS-unclassifiable (MDS-U), 4.5%. Subjects were administered questionnaires and information on previous disease, work histories and exposures to potential etiologic agents such as benzene (BZ) was obtained. A total of 80/649 (13.2%) were determined to have some BZ exposure. The frequency of clonal cytogenetic abnormalities in all MDS was 30%, the most common being +8>del(20)q>del(7q)>del(5q), while the analogous frequency in BZ-exposed cases was only 24%. To further investigate the chara...Continue Reading

References

May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R D IronsV A Henry
May 1, 1993·Stem Cells·R D Irons, W S Stillman
Apr 15, 1997·Cancer·D H BiesmaL F Verdonck
Dec 1, 1996·Environmental Health Perspectives·R D Irons, W S Stillman
Dec 1, 1996·Environmental Health Perspectives·R D Irons, W S Stillman
Dec 9, 1997·Journal of the National Cancer Institute·G A Niazi, A F Fleming
Dec 26, 2001·American Journal of Respiratory and Critical Care Medicine·A KanehiroE W Gelfand
Nov 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhijian QianMichelle M Le Beau
Nov 25, 2003·British Journal of Haematology·G-A BanatHans Pralle
Sep 24, 2004·Leukemia Research·A John Barrett
Feb 11, 2005·The New England Journal of Medicine·Mario Cazzola, Luca Malcovati
Sep 27, 2005·Leukemia Research·Richard D IronsHua Fu

❮ Previous
Next ❯

Citations

Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Aug 13, 2011·Journal of Occupational and Environmental Hygiene·Thomas W ArmstrongA Robert Schnatter
Nov 1, 2012·Journal of the National Cancer Institute·A Robert SchnatterLesley Rushton
Sep 18, 2015·International Journal of Environmental Research and Public Health·Juan ZhangYuepu Pu
Oct 14, 2010·Critical Reviews in Toxicology·David GalbraithDennis Paustenbach
Feb 6, 2014·Annals of the New York Academy of Sciences·Helmut GreimRobert Snyder
Mar 13, 2014·Annals of the New York Academy of Sciences·Richard D Irons, Patrick J Kerzic
Jan 26, 2013·Critical Reviews in Toxicology·Scott M ArnoldA Robert Schnatter
Aug 24, 2011·Toxicology Mechanisms and Methods·David W PyattColleen A Cushing
Nov 7, 2013·Advances in Hematology·Ethan A Natelson, David Pyatt
Mar 13, 2010·Advances in Hematology·Ethan A Natelson, David Pyatt
Jun 9, 2016·Journal of Toxicology and Environmental Health. Part a·Xing MengYuepu Pu
Sep 8, 2016·International Journal of Cancer. Journal International Du Cancer·Jenny N PoynterErica Warlick
Feb 2, 2017·Journal of Occupational and Environmental Medicine·G Bruce CopleyPatrick Kerzic
Dec 16, 2017·Critical Reviews in Toxicology·Sherilyn A Gross, Dennis J Paustenbach
May 11, 2018·Critical Reviews in Toxicology·Wenchao Li, A Robert Schnatter
Sep 18, 2020·Toxicology Letters·Colin M NorthStephen D Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.